Previous 10 | Next 10 |
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases PR Newswire BERWYN, Pa. , Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a cli...
Shares of micro-cap clinical-stage biotech Annovis Bio ( NYSE: ANVS ) gained as much as 17.2% to $12.35 in Thursday mid-day trading, after H.C. Wainwright research initiated the stock with a buy rating and gave it a $40 price target, implying a nearly 280% upside to its shar...
Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders PR Newswire BERWYN, Pa. , Sept. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative...
Annovis Bio ( NYSE: ANVS ) said Monday it appointed Henry Hagopian III as CFO , effective immediately. Jeff McGroarty stepped down as CFO to pursue other interests. McGroarty will assist in transition of his duties over the next several weeks. Hagopian most recentl...
Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer PR Newswire BERWYN, Pa. , Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative dis...
The share of the clinical-stage biotech Annovis Bio ( NYSE: ANVS ) added ~7% on low volume in the pre-market trading Wednesday after the company announced the dosing of the first patient in its Phase 3 clinical trial for lead asset buntanetap in early Parkinson's Disease (PD)....
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease PR Newswire BERWYN, Pa. , Aug. 24, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug plat...
Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update PR Newswire BERWYN, Pa. , Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing n...
Annovis Bio to Participate on Alzheimer's Association International Conference Panel PR Newswire The Panel will be Moderated by Jeffrey Cummings , MD, ScD, and Krista Lanctôt, Ph.D. BERWYN, Pa. , Aug. 1, 2022 /PRNewswire/ -- Annovis Bio, ...
Annovis Bio to Present at the Alzheimer's Association International Conference PR Newswire Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings , ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...